Gyre Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Accounts Receivable of -$4.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $4.47M, a 5.40% increase year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$8.57M, a 1287.40% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $4.83M, a 321.03% increase year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $1.01M.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $10.81M, a 105.55% increase from fiscal 2024.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $5.26M.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$285.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2021 was -$1.50M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $4.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$4.10M 10-Q · filed 2026-08-07 | $725.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.74M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | -$8.57M 10-Q · filed 2026-05-08 | -$3.75M derived: sum of 2 quarters · filed 2026-05-08 | -$2.73M derived: sum of 3 quarters · filed 2026-05-08 | $1.51M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $5.84M derived: sum of 2 quarters · filed 2026-03-13 | $10.08M derived: sum of 3 quarters · filed 2026-08-07 | $10.81M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $5.26M derived: sum of 2 quarters · filed 2026-08-07 | $5.98M 10-Q · filed 2025-11-07 | $7.13M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $4.97M 10-Q · filed 2026-08-07 | $6.11M derived: sum of 3 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $722.00K 10-Q · filed 2026-05-08 | $1.87M derived: sum of 2 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $5.26M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $4.11M 10-Q · filed 2025-11-07 | ||||
| 2023-12-31 | -$285.00K 10-K · filed 2025-03-17 | ||||
| 2022-03-31 | -$1.05M 10-Q · filed 2022-05-09 | -$350.00K derived: sum of 2 quarters · filed 2022-05-09 | -$1.21M derived: sum of 3 quarters · filed 2022-05-09 | -$242.00K derived: sum of 4 quarters · filed 2022-05-09 | |
| 2021-12-31 | $704.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$153.00K derived: sum of 2 quarters · filed 2022-03-31 | $812.00K derived: sum of 3 quarters · filed 2022-03-31 | -$1.50M 10-K · filed 2022-03-31 | |
| 2021-09-30 | -$857.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $108.00K derived: sum of 2 quarters · filed 2021-11-12 | -$2.20M 10-Q · filed 2021-11-12 | -$441.00K derived: sum of 4 quarters · filed 2022-05-09 | |
| 2021-06-30 | $965.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.34M 10-Q · filed 2021-08-05 | $416.00K derived: sum of 3 quarters · filed 2022-05-09 | -$17.00K derived: sum of 4 quarters · filed 2022-05-09 | |
| 2021-03-31 | -$2.31M 10-Q · filed 2022-05-09 | -$549.00K derived: sum of 2 quarters · filed 2022-05-09 | -$982.00K derived: sum of 3 quarters · filed 2022-05-09 | -$360.00K derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.32M derived: sum of 2 quarters · filed 2022-03-31 | $1.95M derived: sum of 3 quarters · filed 2022-03-31 | -$11.69M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$433.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $189.00K derived: sum of 2 quarters · filed 2021-11-12 | -$13.45M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $622.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$13.01M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$13.63M 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $15.00M 10-K · filed 2021-03-04 | ||||
| 2017-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$110.00K derived: sum of 2 quarters · filed 2019-03-08 | -$203.00K derived: sum of 3 quarters · filed 2019-03-08 | -$7.00K 10-K · filed 2019-03-08 | |
| 2017-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$176.00K derived: sum of 2 quarters · filed 2017-11-02 | $20.00K 10-Q · filed 2017-11-02 | -$50.00K derived: sum of 4 quarters · filed 2018-03-19 | |
| 2017-06-30 | -$93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $103.00K 10-Q · filed 2017-08-03 | $33.00K derived: sum of 3 quarters · filed 2018-03-19 | -$328.00K derived: sum of 4 quarters · filed 2018-03-19 | |
| 2017-03-31 | $196.00K 10-Q · filed 2017-05-11 | $126.00K derived: sum of 2 quarters · filed 2018-03-19 | -$235.00K derived: sum of 3 quarters · filed 2018-03-19 | -$221.00K derived: sum of 4 quarters · filed 2018-03-19 | |
| 2016-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | -$431.00K derived: sum of 2 quarters · filed 2018-03-19 | -$417.00K derived: sum of 3 quarters · filed 2018-03-19 | -$461.00K 10-K · filed 2018-03-19 | |
| 2016-09-30 | -$361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$347.00K derived: sum of 2 quarters · filed 2017-11-02 | -$391.00K 10-Q · filed 2017-11-02 | -$547.00K derived: sum of 4 quarters · filed 2017-11-02 | |
| 2016-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$30.00K 10-Q · filed 2017-08-03 | -$186.00K derived: sum of 3 quarters · filed 2017-08-03 | $57.00K derived: sum of 4 quarters · filed 2017-08-03 | |
| 2016-03-31 | -$44.00K 10-Q · filed 2017-05-11 | -$200.00K derived: sum of 2 quarters · filed 2017-05-11 | $43.00K derived: sum of 3 quarters · filed 2017-05-11 | -$252.00K derived: sum of 4 quarters · filed 2017-05-11 | |
| 2015-12-31 | -$156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $87.00K derived: sum of 2 quarters · filed 2017-03-08 | -$208.00K derived: sum of 3 quarters · filed 2017-03-08 | $79.00K 10-K · filed 2017-03-08 | |
| 2015-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$52.00K derived: sum of 2 quarters · filed 2016-11-03 | $235.00K 10-Q · filed 2016-11-03 | $240.00K derived: sum of 4 quarters · filed 2016-11-03 | |
| 2015-06-30 | -$295.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$8.00K 10-Q · filed 2016-08-04 | -$3.00K derived: sum of 3 quarters · filed 2016-08-04 | $5.00K derived: sum of 4 quarters · filed 2016-08-04 | |
| 2015-03-31 | $287.00K 10-Q · filed 2016-05-05 | $292.00K derived: sum of 2 quarters · filed 2016-05-05 | $300.00K derived: sum of 3 quarters · filed 2016-05-05 | ||
| 2014-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $13.00K derived: sum of 2 quarters · filed 2016-03-09 | -$1.00K 10-K · filed 2016-03-09 | -$1.03K 8-K/A · filed 2015-10-23 | |
| 2014-09-30 | $8.00K derived: 10-Q 9 month − 8-K/A 6 month · filed 2015-11-05 | -$6.00K 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | -$14.00K 8-K/A · filed 2015-10-23 | ||||
| 2013-12-31 | $52.00K 10-K · filed 2016-03-09 | $51.26K 8-K/A · filed 2015-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |